ReviewClinical and experimental vaccine research2018
Recent progress in microneme-based vaccines development against
Review in Clinical and experimental vaccine research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on efficiency of microneme proteins to induce protective immunity against Toxoplasma gondii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Pooled it
- HarnessingAnnals of medicine · 2026Review
- Elevated Liver Enzymes and Genotype I of T. gondii Among Liver Cancer Patients: Evidence of a Potential Link.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Article
- Sialic Acid-Binding Protein-1 (SABP1) ofJournal of parasitology research · 2025Article
- In silico evaluation of Toxoplasma gondii rhoptry neck proteins (TgRONs) for potential immunogenic epitopes.EXCLI journal · 2025Article
- In Silico-Based Investigation of the Immunogenicity and Biochemical Attributes ofJournal of parasitology research · 2025Article
- IL-36 Gamma: A Novel Adjuvant Cytokine Enhancing Protective Immunity Induced by DNA Immunization with TGIST and TGNSM AgainstMicroorganisms · 2024Article
- Effective factors in the pathogenesis ofHeliyon · 2024Review
- Global prevalence ofParasite epidemiology and control · 2024Review
- Review
- In Silico Analysis of the ROP29 Protein as a Vaccine Candidate AgainstJournal of parasitology research · 2024Article
- Global Proteome-Wide Analysis of Cysteine S-Nitrosylation inMolecules (Basel, Switzerland) · 2023Article
- Toxoplasmosis vaccines: what we have and where to go?NPJ vaccines · 2022Review
- Influenza virus-like particle vaccine containing both apical membrane antigen 1 and microneme-associated antigen proteins of Plasmodium berghei confers protection in mice.BMC immunology · 2022Article
- Vaccination with recombinantFrontiers in veterinary science · 2022Article
- REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.The Journal of parasitology · 2021Review
- Article
- Bioinformatics analysis of calcium-dependent protein kinase 4 (CDPK4) as Toxoplasma gondii vaccine target.BMC research notes · 2021Article
- A Novel Vaccine Candidate: RecombinantFrontiers in veterinary science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasmosis is a cosmopolitan zoonotic disease, which infect several warm-blooded mammals. More than one-third of the human population are seropositive worldwide. Due to the high seroprevalence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.